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Houslay	 Viagra	…..	 Page		 5	
expression.	(RED	=	brake	supplied	by	PDE5;	GREEN	=	proliferative	phenotype	switching	signals	
provided	by	PDE5	inhibitors	and,	potentially,	hypoxia).	
	
Panel	(b).	In	V600E-BRAF	expressing	melanocytes,	the	brake	(red)	that	PDE5A	exerts	on	cGMP	
driven	metastasis	is	released	when	PDE5	levels	are	diminished	through	activation	of	the	
transcriptional	repressor,	BRN2	via	an	activated	BRAF/Erk	pathway.		Populations	of	V600E-BRAF	
expressing	melanocytes	show	variation	in	the	level	of	PDE5	reduction	and	those	expressing	
residual	PDE5	will	be	susceptible	to	the	action	of	PDE5	inhibitors,	which	will	potentiate	the	
development	of	a	de-differentiated,	metastatic	phenotype.		It	is	proposed	here	that	hypoxia	(GREY	
BOX)	may	also	amplify	switching	to	a	metastatic	phenotype,	in	this	case	by	lowering	MITF	levels	in	
a	Hif1a-driven	fashion	in	order	to	remove	the	inhibitory	effect	of	miR-211	on	BRN2	transcription	
and	so	decreasing	PDE5A	expression.		(RED	=	brake	supplied	by	PDE5;	GREEN	=	metastatic	
phenotype	switching	signals	provided	by	PDE5	inhibitors,	activated	V600E-BRAF	and,	potentially,	
hypoxia).	
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